1997 IPO
Vericel Corp Stock
Vericel Corp is engaged in the development of treatments for critical cardiovascular diseases.
Sign up today and learn more about Vericel Corp Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vericel Corp Stock
Vericel (formerly Aastrom Biosciences) is developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI™, a third-generation autologous chondrocyte implantation product for the treatment of focal chondral cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Funding History
| March 2012 | $40.0M |
|---|
Management
Chief Scientific Officer
Ronnda L. Bartel
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
